293 cells were transfected with anti-BCMA-scFv and RFP tag. 2e5 of the cells were stained with B. FITC-Labeled Human BCMA, His Tag (Cat. No. BCA-HF2H1, 1 µg/ml) and C. FITC-labeled protein control. A. Non-transfected 293 cells and C. FITC-labeled protein control were used as negative control. RFP was used to evaluate CAR (anti-BCMA-scFv) expression and FITC was used to evaluate the binding activity of FITC-Labeled Human BCMA, His Tag (Cat. No. BCA-HF2H1) (QC tested).
Anti-BCMA Neutralizing Antibody, Mouse IgG1 (Clone: AM43, Cat. No. BCA-M43) captured on CM5 chip via anti-mouse antibodies surface can bind Human BCMA, His Tag (Cat. No. BCA-H522y) with an affinity constant of 0.388 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Belantamab mafodotin | GSK-2857916; GSK2857916 | Approved | Glaxosmithkline Plc | BLENREP | EU | Multiple Myeloma | s:29:"Glaxosmithkline (Ireland) Ltd"; | 2020-08-05 | Multiple Myeloma | Details |
| Idecabtagene vicleucel | bb-2121 | Approved | Bluebird Bio | United States | Multiple Myeloma | s:12:"Celgene Corp"; | 2021-03-26 | Multiple Myeloma | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| LCAR-B4822M | LCAR-B4822M | Phase 1 Clinical | Genscript Biotech Corp | Multiple Myeloma | Details |
| SEA-BCMA | SEA-BCMA; SGN-BCMA | Phase 1 Clinical | Seattle Genetics | Multiple Myeloma | Details |
| REGN-5459 | REGN-5459 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Multiple Myeloma | Details |
| HPN-217 | HPN-217 | Phase 2 Clinical | Harpoon Therapeutics | Multiple Myeloma | Details |
| Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) | Phase 1 Clinical | Wuhan Union Hospital, Shengyan Pharmaceutical Technology | Multiple Myeloma | Details | |
| Anti-BCMA CAR T-cell therapy (Arcellx) | CART-ddBCMA | Phase 1 Clinical | Arcellx | Multiple Myeloma | Details |
| BCMA CAR-T Cells (Pregene) | Phase 1 Clinical | Shenzhen Prekin Biopharmaceutical Co Ltd | Multiple Myeloma | Details | |
| BCMA CAR-T cell therapy (Hebei Senlang Biotechnology) | Details | ||||
| CTX-120 | CTX-120 | Phase 1 Clinical | Crispr Therapeutics | Multiple Myeloma | Details |
| CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University | Multiple Myeloma | Details | |
| Anti-BCMA CAR-T cell therapy (Xinqiao Hospital) | Phase 1 Clinical | Multiple Myeloma | Details | ||
| BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) | Phase 2 Clinical | People'S Liberation Army General Hospital Military Service | Multiple Myeloma | Details | |
| TNB-383B | TNB-383B | Phase 1 Clinical | Teneobio | Multiple Myeloma | Details |
| Anti BCMA chimeric antigen receptor T cell therapy (Chongqing Precision Biotech) | Phase 2 Clinical | Chongqing Precision Biotechnology Co Ltd | Multiple Myeloma | Details | |
| Anti-BCMA CAR-T cell therapy (PersonGen Biomedicine) | Phase 1 Clinical | Multiple Myeloma | Details | ||
| Anti BCMA CAR T cell therapy (Shanghai Hrain Biotechnology) | BCMA-CART | Phase 1 Clinical | Hrain Biotechnology Co Ltd | Multiple Myeloma | Details |
| BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) | Phase 1 Clinical | The First Affiliated Hospital Of Nanchang University | Multiple Myeloma | Details | |
| GC-012F | GC-012F | Phase 1 Clinical | Genxi Biotechnology (Shanghai) Co Ltd | Multiple Myeloma | Details |
| P-BCMA-101 | P-BCMA-101 | Phase 2 Clinical | Poseida Therapeutics | Multiple Myeloma | Details |
| Anti BCMA CART cell therapy (Shanghai YaKe Biotechnology) | Phase 1 Clinical | Yake Biotechnology | Multiple Myeloma | Details | |
| BCMA CAR-NK 92 cell therapy (Asclepius Technology Company Group) | Phase 2 Clinical | Asclepius Technology Company Group | Multiple Myeloma | Details | |
| Anti-BCMA CAR T cell therapy (Wuhan Bio-Raid Biotechnology) | Clinical | Wuhan Bio-Raid Biotechnology | Hematologic Neoplasms | Details | |
| BCMA-CS1 cCAR T cell therapy (iCell Gene Therapeutics) | Phase 1 Clinical | Icell Gene Therapeutics | Multiple Myeloma | Details | |
| ACTR 087/SEA BCMA combination therapy | Phase 1 Clinical | Unum Therapeutics | Multiple Myeloma | Details | |
| Autologous BCMA-directed CAR T-cell therapy (The First Affiliated Hospital of Soochow University) | Phase 3 Clinical | The First Affiliated Hospital Of Soochow University | Multiple Myeloma | Details | |
| CC-98633 | CC-98633 | Phase 1 Clinical | Celgene Corp | Multiple Myeloma | Details |
| anti-BCMA CAR T-cell Therapy (Juno Therapeutics) | FCARH-143; ET140-CAR; MCARH-171; JCARH-125; ET-140 | Phase 2 Clinical | Juno Therapeutics | Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
| BCMA Targeted CAR-T Cell Therapy (Yake Biotechnology) | CBG-002 CAR-T | Phase 1 Clinical | Yake Biotechnology Ltd | Multiple Myeloma | Details |
| HBI-0101 | HBI-0101 | Hadassah Medical Organization | Details | ||
| CC-99712 | CC-99712 | Phase 1 Clinical | Celgene Corp | Multiple Myeloma | Details |
| MEDI-2228 | MEDI-2228 | Phase 1 Clinical | Medimmune Llc | Multiple Myeloma | Details |
| ALLO-715 | ALLO-715 | Phase 1 Clinical | Cellectis, Allogene Therapeutics | Multiple Myeloma | Details |
| KITE-585 | KITE-585 | Phase 1 Clinical | Kite Pharma, National Cancer Institute | Multiple Myeloma | Details |
| PBCAR-269A | PBCAR-269A | Phase 2 Clinical | Precision Biosciences | Multiple Myeloma | Details |
| CAR-BCMA T cell therapy | CT-053-CARsgen | Phase 2 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd | Multiple Myeloma | Details |
| Human BCMA chimeric antigen receptor autologous T cell（Nanjing Reindeer Medical Technology） | CT103A | Phase 2 Clinical | Nanjing Iaso Biotherapeutics Co Ltd, Innovent Biologics(Suzhou) Co Ltd | Multiple Myeloma | Details |
| CXCR4 modified anti-BCMA CAR T cell therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Multiple Myeloma | Details | |
| CC-93269 | EM-901; CC-93269 | Phase 1 Clinical | Celgene Corp | Multiple Myeloma | Details |
| EMB-06 | EMB-06 | Phase 2 Clinical | Shanghai Epimab Biotherapeutics, Inc | Multiple Myeloma | Details |
| Allogeneic anti-BCMA CAR-T (Legend) | Phase 1 Clinical | Multiple Myeloma | Details | ||
| Teclistamab | JNJ-64007957; JNJ-64007959; JNJ-7957 | Phase 2 Clinical | Janssen Global Services Llc, Genmab | Hematologic Neoplasms; Multiple Myeloma | Details |
| BCMA CAR-T cell therapy (Chongqing Precision Biotech) | Phase 2 Clinical | Chongqing Precision Biotechnology Co Ltd | Plasmacytoma; Multiple Myeloma; Neoplasms, Plasma Cell | Details | |
| PF-06863135 | PF-06863135 | Phase 2 Clinical | Pfizer Pharmaceuticals Ltd (China) | Multiple Myeloma | Details |
| BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) | Phase 1 Clinical | Icell Gene Therapeutics | Multiple Myeloma | Details | |
| AMG-420 | AMG-420; BI-836909 | Phase 1 Clinical | Micromet | Multiple Myeloma | Details |
| bb-21217 | bb-21217 | Phase 1 Clinical | Bluebird Bio | Multiple Myeloma | Details |
| Anti-BCMA/CD19 CAR-T（Autolus） | Details |
This web search service is supported by Google Inc.
A-Z
